Establishment Labs Holdings Inc. $ESTA is Union Square Park Capital Management LLC’s 10th Largest Position

Union Square Park Capital Management LLC reduced its holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 48.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 90,000 shares of the company’s stock after selling 85,000 shares during the period. Establishment Labs makes up 3.2% of Union Square Park Capital Management LLC’s portfolio, making the stock its 10th largest holding. Union Square Park Capital Management LLC’s holdings in Establishment Labs were worth $6,559,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in ESTA. Quarry LP purchased a new position in shares of Establishment Labs in the 3rd quarter worth $34,000. Kestra Advisory Services LLC purchased a new position in shares of Establishment Labs in the 4th quarter worth $47,000. Osaic Holdings Inc. grew its stake in shares of Establishment Labs by 900.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after buying an additional 1,800 shares in the last quarter. Truist Financial Corp purchased a new position in shares of Establishment Labs in the 4th quarter worth $200,000. Finally, PharVision Advisers LLC purchased a new position in shares of Establishment Labs in the 3rd quarter worth $203,000. 72.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ESTA has been the subject of a number of recent research reports. BTIG Research lifted their price objective on shares of Establishment Labs from $88.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Needham & Company LLC lifted their price objective on shares of Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Tuesday, February 24th. Mizuho lifted their price target on shares of Establishment Labs from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. TD Cowen reaffirmed a “buy” rating on shares of Establishment Labs in a research note on Monday, June 8th. Finally, Canaccord Genuity Group lifted their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Establishment Labs has a consensus rating of “Moderate Buy” and an average price target of $87.14.

Establishment Labs Price Performance

ESTA stock opened at $82.57 on Wednesday. Establishment Labs Holdings Inc. has a 12 month low of $33.35 and a 12 month high of $86.00. The company has a current ratio of 2.96, a quick ratio of 1.91 and a debt-to-equity ratio of 16.82. The company has a 50-day moving average price of $69.81 and a 200 day moving average price of $69.38. The stock has a market cap of $2.43 billion, a PE ratio of -55.42 and a beta of 1.11.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The firm had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $57.40 million. During the same period in the prior year, the firm posted ($0.70) earnings per share. Establishment Labs’s revenue for the quarter was up 44.7% on a year-over-year basis. Equities research analysts anticipate that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current year.

Insider Activity at Establishment Labs

In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 105,000 shares of the business’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total value of $7,919,100.00. Following the completion of the sale, the director directly owned 927,504 shares of the company’s stock, valued at $69,952,351.68. The trade was a 10.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders have sold 330,000 shares of company stock worth $22,854,538. 9.99% of the stock is currently owned by insiders.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.